# Aligos Therapeutics, Inc. (ALGS) · Edgar & Edgarette company card

> Aligos Therapeutics (ALGS) saw revenue fall 39.5% in FY2025 to $2 million, operating margin -4025% against a -15.8% median for biological products, (no diagnostic substances), equity 60.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1799448 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ALGS) · [JSON](https://www.pops4.com/boards/company/ALGS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2M |
| Revenue growth, 1 year | -39.5% |
| Revenue growth per year | — |
| Operating margin | -4024.9% (prior year -2469.0%) |
| Net margin | -1106.7% |
| Operating cash flow | −$83M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $18M |
| Long-term debt | — |
| Total assets | $89M |
| Total equity | $54M |
| Equity ÷ assets | 60.5% |
| Return on equity | -45.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -24.15 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -4024.9% in FY2025; revenue is hard to predict: its 80% range is ±28%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $2.2M (FY2025). Experience: revenue down 39.5% on the year; operating margin -4024.9%, down from -2469.0%. Soundness: equity 60.5% of assets, return on equity -45.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $971K and $1.7M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -4024.9% against a -15.8% median; growth -39.5% against 21.4%.

Range logged 2026-09-20, receipt a941ecc449e75333, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-06-26 ([filing](https://www.sec.gov/Archives/edgar/data/1799448/000119312526285426/0001193125-26-285426-index.htm))

## Recent filings

- 8-K · filed 2026-09-15 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1799448/000119312526391880/0001193125-26-391880-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1799448/000119312526336851/0001193125-26-336851-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/0001171843-26-005294-index.htm)
- 8-K · filed 2026-06-26 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1799448/000119312526285426/0001193125-26-285426-index.htm)
- 10-Q · filed 2026-05-07 · [filing](https://www.sec.gov/Archives/edgar/data/1799448/000119312526212001/0001193125-26-212001-index.htm)
- 8-K · filed 2026-05-07 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1799448/000117184326003156/0001171843-26-003156-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001799448.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1799448

## Cite

POPS4, Edgar & Edgarette: Aligos Therapeutics, Inc. (ALGS) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ALGS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.